GSE126463 pomalidomide MM1.S 1 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE126463_pomalidomide_MM1.S_1_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE126463_pomalidomide_MM1.S_1_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE126463_pomalidomide_MM1.S_1_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE126463_pomalidomide_MM1.S_1_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

HLA complex P5

Gene

non-coding RNA activated by DNA damage

Gene

long intergenic non-protein coding RNA 511

Gene

HERC2 pseudogene 2

Gene

small nucleolar RNA host gene 12

Gene

long intergenic non-protein coding RNA, p53 induced transcript

Gene

endogenous Bornavirus like nucleoprotein 3, pseudogene

Gene

CD27 antisense RNA 1

Gene

TMEM147 antisense RNA 1

Gene

AFAP1 antisense RNA 1


  • Gene

    non-coding RNA activated by DNA damage


  • Gene

    long intergenic non-protein coding RNA 511


  • Gene

    HERC2 pseudogene 2


  • Gene

    small nucleolar RNA host gene 12


  • Gene

    long intergenic non-protein coding RNA, p53 induced transcript


  • Gene

    endogenous Bornavirus like nucleoprotein 3, pseudogene


  • Gene

    CD27 antisense RNA 1


  • Gene

    TMEM147 antisense RNA 1


  • Gene

    AFAP1 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.